Oncology Test Portfolio

OncoGxSelect OncoGxSelect™

OncoGxSelect™ analyzes a patient’s tumor for genetic mutations frequently found in select cancers. This test utilizes Next Generation Sequencing (NGS) technology to detect alterations in 12 known oncogenes and is aligned with well-established molecular testing guidelines. Actionable results help guide therapeutic decisions related to targeted cancer therapy. Additionally, OncoGxSelect™ detects all types of mutations (SNV, gene fusion, Indel, CNV) with a high degree of accuracy.

View OncoGxOne™ Comprehensive Panel

Target Oncogenes

ALK BRAF EGFR ERBB2 KIT KRAS
MAP2K1 MET NRAS PIK3CA RET ROS1

Types of Alterations Detected

SNVs1 OncoGxSelect™

SNVs

Fusions OncoGxSelect™

Fusions

CNVS2 OncoGxSelect™

CNVs

Indels OncoGxSelect™

Indels

Relevant Solid Tumor Types

Gene Variant Type Responsive Resistant
ALK EML4-ALK Fusion Crizotinib, Ceritinib, Alectinib Gefitinib, Erlotinib, Afatinib
KIF5B-ALK
TFG-ALK
T1151_L1152insT Indel   Crizotinib
L1152R SNV  
C1156Y  
F1174L  
L1196M Brigatinib
G1202R
S1206Y  
G1269A  
BRAF V600E SNV Vemurafenib, Dabrafenib, Dabrafenib+Trametinib  
ERBB2 A775_G776insYVMA Indel Trastuzumab, Afatinib  
G776_777insVC  
Exon20_ins  
G776L SNV Trastuzumab  
EGFR G719A SNV Gefitinib, Erlotinib  
G719C  
G719S  
D761Y   Gefitinib, Erlotinib
K745_A750del Indel Gefitinib, Erlotinib, Afatinib  
E746_A750del  
E746_A750delELREA  
E746_S752delinsA  
L747_S752del  
Exon19_del  
A763_Y764insFQEA  
D770_N771insSVD   Gefitinib, Erlotinib
Exon20_ins  
T790M SNV Osimertinib
C797S   Osimertinib
L858R Gefitinib, Erlotinib, Afatinib  
L861Q Gefitinib, Erlotinib  
KRAS G12A SNV   Gefitinib, Erlotinib
G12C  
G12D  
G12R  
G12S  
G12V  
G13A  
G13C  
G13D  
G13R  
G13S  
G13V  
Q61H  
Q61K  
Q61L  
Q61R  
MET Amplification CNV Crizotinib  
Exon14_skipping Fusion  
RET NCOA4-RET Fusion Cabozantinib  
CCDC6-RET  
KIF5B-RET  
ROS1 CD74-ROS1 Fusion Crizotinib  
GOPC-ROS1  
SLC34A2-ROS1  
EZR-ROS1  
SDC4-ROS1  
TPM3-ROS1  
LRIG3-ROS1  
Gene Variant Type Responsive Resistant
BRAF V600E SNV Dabrafenib+Trametinib, Vemurafenib+Cobimetinib
V600K Dabrafenib+Trametinib, Vemurafenib+Cobimetinib, Vemurafenib, Dabrafenib
KIT Amplification CNV Imatinib
W557R SNV
V559A
V560D
L576P
K642E
MAP2K1 C121S SNV Trametinib
Gene Variant Type Responsive Resistant
ALK STRN-ALK Fusion Crizotinib, Ceritinib
EML4-ALK
BRAF V600E SNV Vemurafenib, Dabrafenib
EGFR Amplification CNV Vandetanib
MET Amplification CNV Cabozantinib
RET NCOA4-RET Fusion Vandetanib, Cabozantinib
CCDC6-RET
C634W SNV Vandetanib
C634R
C634Y
M918T
Gene Variant Type Responsive Resistant
N/A WT Cetuximab, Panitumumab
BRAF V600E SNV Cetuximab, Panitumumab
KRAS G12A SNV Cetuximab, Panitumumab
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
K117N
A146P
A146T
A146V
NRAS G12A SNV Cetuximab, Panitumumab
G12C
G12D
G12R
G12S
G12V
G13A
G13C
G13D
G13R
G13S
G13V
Q61H
Q61K
Q61L
Q61R
Gene Variant Type Responsive Resistant
ERBB2 Amplification CNV Trastuzumab,  Trastuzumab+Chemotherapy
EGFR Overexpression Nimotuzumab
KIT WT Regorafenib Imatinib
L576P SNV Imatinib
W557R
V559A
K642E
V560del Indel
PDGFRA D842V SNV Dasatinib Imatinib
Gene Variant Type Responsive Resistant
ERBB2 Amplification CNV Trastuzumab,  Trastuzumab+Chemotherapy
PIK3CA H1047R SNV Temsirolimus, Everolimus

OncoGxSelect™ Report 

OncoGxOne__Plus_Sample_report_thumb OncoGxSelect™

OncoGxSelect™ Information Sheet 

OncoGxSelect_Info_sheet_thumb-1 OncoGxSelect™